Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | Outcomes of TP53-mutant AML with venetoclax and decitabine

Marina Konopleva • 30 Nov 2020

ASH 2020

Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the outcomes of TP53-mutant acute myeloid leukemia patients treated with venetoclax and decitabine. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultancy (includes expert testimony): AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji
Equity ownership: Stocks, Reata Pharmaceuticals
Research funding: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca
Patents and royalties: Reata Pharmaceuticals

Advancements in AML: an update from ASH 2023

Marina Konopleva • 8 Dec 2023

The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML

Marina Konopleva • 8 Dec 2023

10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML

Marina Konopleva • 8 Dec 2023

Targeting mitochondrial metabolism to eradicate MRD in AML

Marina Konopleva • 8 Dec 2023

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024